Impact of Herpes simplex virus load and red blood cells in cerebrospinal fluid upon herpes simplex meningo-encephalitis outcome by Julien Poissy et al.
RESEARCH ARTICLE Open Access
Impact of Herpes simplex virus load and red blood
cells in cerebrospinal fluid upon herpes simplex
meningo-encephalitis outcome
Julien Poissy1*, Karen Champenois2, Anny Dewilde3, Hugues Melliez1, Hugues Georges4, Eric Senneville1
and Yazdan Yazdanpanah1,2
Abstract
Background: Herpes simplex encephalitis (HSE) often leads to severe disability or death. Factors usually associated
with outcome include Simplified Acute Physiology Score, age and delay of initiation of acyclovir treatment.
Our aim was to determine the impact of Herpes simplex virus (HSV) load in cerebrospinal fluid (CSF) upon HSE
outcome.
Methods: We retrospectively determined HSV load in the CSF of 43 patients with confirmed HSE, hospitalized in
northern France from 1998 to 2005, using CSF samples collected the day of hospital admission and stored at −20°C.
We analyzed the association between HSV load and mortality/morbidity by the Glasgow Outcome Scale. Fisher’s
exact test and Wilcoxon’s test were used for statistical analysis.
Results: The M/F sex ratio was 1.7 and median patient age was 61 years. Median HSV load in CSF was 2.0 log
copies/μL (IQR 25-75=1.2-2.6). The mortality rate was 32.6% six months after HSE diagnosis. Higher age was
associated with mortality (p=0.03). Longer delay in acyclovir initiation tended to be associated with higher mortality
but did not reach statistical significance (p=0.08). Severe disability and death due to HSV were associated with a
higher Knaus score (p=0.004), later acyclovir initiation (p=0.006), older age (p=0.04) and presence of red blood cells
in CSF (p=0.05). HSV load in CSF was neither associated with mortality (p=1.00) nor with morbidity (p=0.90).
Conclusion: In this study, HSV load in CSF was not found to be associated with poor outcome in patients with
HSE. These data do not support measurement of HSV load at admission in patients with HSE.
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Background
Herpes simplex virus (HSV) is the primary cause of viral
necrotizing encephalitis in developed countries; when
untreated, the disease has a 70% mortality rate [1,2].
Despite the introduction of acyclovir treatment, mortal-
ity and persistent neurologic impairment due to HSV
encephalitis (HSE) remain high [3,4]: 15 to 20% of
patients with HSE die and about 60% of surviving
patients develop long-term neurological sequels [1,5].
Therefore, it is important to identify factors associated
with severe morbidity and mortality in HSE.
Factors commonly reported to be associated with HSE
outcome are age, level of consciousness at initial man-
agement of the patient [6] and time to start of acyclovir
treatment [5]. Previous histopathological descriptions of
HSE also showed a relationship between a high number
of viral particles upon brain biopsy and poor disease
outcome [7]. However, since HSV load in the cerebro-
spinal fluid (CSF) is not routinely determined, data on
the impact of high HSV load upon HSE outcome are
scarce and contradictory [8-11].
The aim of this study was to assess the association be-
tween HSV load in CSF (before initiation of acyclovir
treatment) and HSE outcome.
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We conducted a retrospective study in patients diag-
nosed with HSE in northern France from 1998 to 2005.
We focused on patients for whom a CSF sample was
available prior to acyclovir treatment initiation in order
to assess the association between CSF HSV load and
morbidity and mortality six months after HSE onset.
Data collection
Data were collected retrospectively from patient medical
records using a standardized questionnaire. Morbidity
was assessed using the Glasgow Outcome Scale (GOS)
divided into 5 categories (1: good recovery without
neurologic impairment; 2: mild disability; 3: moderate
disability; 4: severe disability; 5: death) [12,13]. The fol-
lowing informations were collected: i) at treatment initi-
ation in the hospital: age, sex, alcohol consumption,
severity of underlying disease, body temperature and
Glasgow coma scale (GCS [13]); ii) during patient stay
in the hospital: CSF cell counts prior to acyclovir initi-
ation and time period between hospital admission, lum-
bar puncture and acyclovir initiation. Severity of the
underlying disease was determined using the Knaus scale
(A: normal health status; B: moderate limitation (impos-
sible to work or study); C: severe limitation (need to
have a third person in daily life); D: bedridden patient)
and the MacCabe score (0: no fatal disease; 1: death in
the next five years; 2: death in the following year)
[14,15].
Measurement of HSV load in CSF
HSV load was measured in CSF of patients with HSE
using a frozen sample taken before acyclovir treatment
was initiated. Samples were prospectively collected and
stored at −20°C. When frozen CSF was available (n=30),
we extracted HSV DNA using the QIAampW DNA Blood
Qiagen kit according to the manufacturer’s instructions.
We performed the extraction and quantified HSV load on
200 μL of the sample for 6 patients and less than 200 μL
for 24 patients. When no CSF was available to extract
DNA (n=13), we quantified the viral load directly on
DNA that had been extracted on the date of sampling
and stored frozen at −20°C. Then, quantification of the
viral load was performed using the artusW HSV-1/2 LC
PCR kit manufactured by Qiagen. This PCR kit uses real
time PCR for quantification and contains a second system
of heterologous amplification to monitor for the possible
presence of inhibitors. It allows the distinction between
HSV1 and 2.
Statistical analysis
First, we used descriptive statistics to evaluate patient
characteristics according to CSF sample availability.
Secondly, we assessed univariate associations between
HSV load (or other variables collected) and HSE out-
come defined as mortality at six months and morbidity
at six months (low morbidity: GOS 1, 2 and 3 versus
high morbidity: GOS 4 and 5).
Non-parametric tests were used for all comparisons.
Fisher’s exact test and Wilcoxon’s test were used to com-
pare qualitative and quantitative variables, respectively.
A significance threshold of 0.05 was retained. Statistical
analysis was performed using SAS software (SAS 9.1,
SAS Institute Inc., Cary, NC, USA).
Ethics statement
All patients included in the study were followed in differ-
ent hospitals from northern France. The care practices
included CSF sampling for diagnosis and management of
these patients with suspected HSE. HSV qualitative PCR
were performed routinely for this diagnosis. We per-
formed quantitative PCR retrospectively on the residual
frozen CSF. No additional sampling was necessary. This
study was approved by the “Comité de Protection des
Personnes Nord Ouest IV”, the ethic committee of Lille
Universitary Hospital.
Results and discussion
Between 1998 and 2005, 78 patients sought care for
HSE in northern France. Those patients belonged to a
previously published cohort [16]. Frozen CSF samples
were available for 43 of them. All of these were from
patients with HSV-1 encephalitis. Characteristics of these
patients are presented in Table 1. Mortality at 6 months
was quite high (32.6%) and severe morbidity (GOS score
4 and 5) was frequent (44.7%). This was not significantly
higher than mortality of non included patients (20.0%)
(p=0.12). Included and not included patients did not differ
for other demographic, clinical or biological main charac-
teristics (data not shown). Characteristics usually linked
to poor prognosis in the literature were found in our
cohort., i.e. age, alcohol consumption, time period be-
tween admission and acyclovir introduction (Table 1,
[1,2,5,6,17,18]).
We first studied factors associated with mortality six
months after HSE onset (Table 2). Median CSF HSV
load was 2.1 log10 copies/μL in patients who survived
vs. 1.7 log10 copies/μl in patients who had died at six
months (Figure 1). The difference was not significant
(p=0.95) and we observed a great dispersion of the viral
load values. Older age was significantly associated with
mortality at six months (71 years in deceased patients vs.
59 years in patients who survived, p=0.03). There was a
trend toward an association between mortality at six
months and longer time between admission and start of
acyclovir treatment (2 days in deceased patients vs. 0 day
in patients who survived, p=0.08).
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Table 1 Characteristics of patients with CSF sample in our cohort
Patients with CSF sample (n=43)
Demographic characteristics
Age in years (median, [IQR]) 61 [50–69]
Sex (n, % of males) 27 62.8%
Mortality
Death at 6 months (n, %) 14 32.6%
Morbidity
Glasgow Outcome Scale, GOS (n, %)
Good recovery to moderate disability (1–3) 21 55.3%
Severe disability and death (4–5) 17 44.7%
Other characteristics
MacCabe score (n, %)
No fatal disease (0) 34 79.1%
Death in the next 1 or 5 years (1–2) 8 19.0%
Knaus score (n, %)
Normal health status (A) 23 54.8%
Moderate limitation to bedridden patients (B-D) 19 45.2%
Time to acyclovir initiation in days (median, [IQR]) 1 [0–2]
Alcohol consumption (n, %) 6 14.0%
Body temperature (°C) (median, [IQR]) 38.9 [38.4–39.5]
GCS score (median, [IQR]) 14 [12–15]
Leukocyte count (cells/μL) (median, [IQR]) 50 [8–142]
Lymphocyte percentage of white cells (median, [IQR]) 80.5 [10–96]
Time to lumbar puncture (days) (median, [IQR]) 1 [0–1]
HSV load (log10 copies/μL) (median, [IQR]) 2.0 1.2–2.6
IQR: Interquartile range.
There are some missing data for GOS, Mac Cabe and Knaus scores and time to acyclovir initiation.
Table 2 Univariate analysis of factors associated with HSE mortality and morbidity
Variables Mortality (n=43) Morbidity (n=39*)
Alive (n=29) Dead (n=14) p Low (n=17) GOS 1-3 High (n=22) GOS 4-5 P
Median HSV load (Log10 copies/μL) 2.1 1.7 0.95 2.0 1.8 0.95
Age in years (median) 59 71 0.03 57 64 0.04
Knaus score (%) 0.07 0.004
Normal health status (A) 64.3 35.7 81,3 18.8
Moderate limitation in bedridden patients (B-D) 35.7 64.3 33.3 66.7
Lymphocytic CSF (%) 66.7 41.7 0.17 80.0 42.1 0.04
Median blood red cell counts in CSF (cells/μL) 4 49 0.17 0 49 0.05
Median time to lumbar puncture (days) 0 1 0.23 0 1 0.02
Median time to acyclovir initiation (days) 0 2 0.08 0 2 0.006
* Morbidity analysis was performed for 38 patients, since Glasgow outcome scale was not available for five patients.
GOS 1–3: Glasgow outcome scale, classes 1 to 3: good recovery to moderate disability.
GOS 4–5: Glasgow outcome scale, classes 4 and 5: severe disability and death.
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We next studied factors associated with morbidity six
months after HSE onset (Table 2). Results were available
for 39 patients, as the functional status was unknown for
4 patients. CSF HSV load distribution by GOS class is
shown in Figure 2. Median HSV load in CSF was 2.0
log10 copies/μL in patients with low morbidity (GOS 1,
2 and 3) versus 1.8 log10 copies/μL in patients with high
morbidity (GOS 4 and 5). The difference was not signifi-
cant (p=0.95). Factors significantly associated with severe
morbidity were: older age (64 vs. 57 in patients with low
morbidity, p=0.04), delayed lumbar puncture (1 day vs. 0
day, p=0.02), delayed acyclovir introduction (2 vs. 0 days,
p=0.006), a worse Knaus score (A: 18.8% vs. 81.3%; B+
C+D: 66.7% vs. 33.3%, p=0.004) and the presence of red
blood cells in the CSF sample (49 cells/μL vs. 0, p=0.05).
A predominance of lymphocytes in the CSF was asso-
ciated with lower morbidity (42% in patients with high
morbidity vs. 80% in those with low morbidity, p=0.04).
We assessed factors associated with HSE outcome in
43 patients with symptomatic HSV encephalitis who
sought care in northern France between 1998 and 2005.
To our knowledge, this cohort is the largest ever used
for evaluating the impact of HSV load in CSF upon HSV
encephalitis outcome. Moreover, we used a technique of
quantitative real time PCR, limiting the risks of false
positive samples. We found no association between HSV
load and HSE outcome, nor in mortality or morbidity
six months after HSE onset.
Our results are consistent with other studies concern-
ing factors usually associated with poor outcome in HSV
encephalitis: older age, delayed initiation of acyclovir
treatment and a high Knaus score [1,2,5,6,17,18].
Regarding the absence of association between CSF
HSV load and HSE outcome, our results are in contrast
to results reported by Dominges et al. [8]. However, in
that study, HSV load was studied as a dichotomous vari-
able with a cut-off of 100 copies/μL separating high and
low viral load levels. In our study, we analyzed the rela-
tionship between viral load and outcome, introducing
viral load as a continuous variable. Our results are in
agreement with Wildeman et al. [10], Ruzek et al. [11]
and Hjalmarsson A et al. [19]. Kamei S et al., who evalu-
ated serial changes of intrathecal viral loads by chemilu-
minescence assay and nested PCR, did not find any
evident association between viral load and outcome ei-
ther [20]. Our results are also concordant with the study
of Schloss et al., comparing nested PCR to quantitative
real-time PCR [21]. However, in that recently published
study, not all patients were treated by acyclovir. In our
cohort, all patients were treated by acyclovir and all
samples were collected before introduction of antiviral
treatment.
The absence of an association between HSE outcome
and CSF HSV load could suggest that the pathogenicity
of HSE may not be directly linked to extent of viral rep-
lication, but rather depends on the host response. This
hypothesis is consistent with the fact that IgG levels
were described to be significantly higher in patients
with good prognostic than in patients with poor out-
come [19].
Surprisingly, in our study, we found a significant asso-
ciation between a high red cell count in CSF and severe
morbidity. To our knowledge, this association had not
been described previously. It can be hypothesized that a
higher red cell count in CSF could reflect more severe
brain cell necrosis, which may be due to an intense and
inappropriate immunological response of the host to
viral aggression. Some experimental data suggested that
an intense and inappropriate inflammatory response
could be harmful, and might explain the higher risk of
morbidity [22,23]. However, this hypothesis remains to
be further elucidated.
Figure 1 Distribution of CSF HSV viral loads by vital status in
43 patients with HSV encephalitis and an available frozen CSF
sample.
Figure 2 Distribution of CSF HSV viral loads by Glasgow
Outcome Scale in the 39 patients for which data were
available.
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Our study had several limitations. First, although our
sample size was greater than in other studies [8,10,11],
the number of patients with available CSF samples was
still small. This limitation is due to the low prevalence of
HSE. Thus, due to the lack of statistical power, we may
not have identified a potentially existing association be-
tween HSV load and HSE outcome. However, we were
able to identify factors that are usually reported to be
associated with poor HSV outcome in the literature
[1,2,5,6]. Second, the risk of selection bias occurrence in
our study was low. Although not all patients with HSE
were enrolled, those with and without available CSF
samples did not statistically differ in their main charac-
teristics. We observed a higher mortality rate in patients
with available CSF samples than in those without. The
reason for this difference in mortality is unclear. How-
ever, this did not bias our findings regarding the impact
of HSV load on HSV outcome. Third, ideally, the impact
of CSF HSV load on HSV encephalitis should be exam-
ined at the onset of first symptoms. This is, however,
unfeasible and unrealistic. Finally, it can be specu-
lated that retrospective determination of HSV load
in frozen samples is not accurate and may lead to
the absence of an association between viral load and
HSE outcome. However, Revello et al. showed the
absence of genetic matter loss in samples frozen at
−20°C [9]. Jerome et al., measured HSV loads in the
same samples directly after sampling and after stor-
age at 4°C for 16 months. HSV loads in freshly ana-
lyzed samples did not differ from those that had
been stored at 4°C [24]. It is to note that in this last
study, three positive specimens were negative upon
retesting after storage. All these samples contained
very low levels of virus even in the original quantita-
tion and the authors estimated that the negative
results may represent the inherent inaccuracy of
quantitation of viral DNA in samples with low levels
of virus rather than a true loss of viral DNA. In our
study, we found 5 negative samples by quantitative
PCR, although they were positive with qualitative
PCR. We think that we encountered the same
phenomenon as Jerome et al.: accurate quantitation
of viral DNA is not possible in samples with low
levels of virus. In addition, we sometimes had to
work with low quantities of CSF due to limited
availability of samples. This occurred more fre-
quently in patients whose samples gave negative
results by quantitative PCR. In one of these 5
patients, enough CSF was available to re-perform a
real time qualitative PCR, which was positive at the
39th cycle, corresponding to a low viral load. Thus,
we can consider that these false negative results by
quantitative PCR do not bias our results, because
they effectively correspond to low HSV loads.
Conclusions
In the present study, we found no relationship between
poor outcome in patients suffering from HSV encephalitis
and HSV load in CSF prior to acyclovir treatment initiation.
But we found a relation between poor outcome and the
presence of red blood cells in CSF. Our results suggest that,
in herpetic meningo-encephalitis, severity is probably not
due to the intensity of viral replication. Whether it is related
to other physiopathological causes, such as intense and in-
appropriate inflammatory responses, remains to be eluci-
dated. According to our results and that of similar studies,
quantitative real-time PCR is not useful to diagnose HSE.
Qualitative real-time PCR assay is perfectly suited.
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